Episode notes
C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.
Podcast
Talking Points
TCTMD · Tech & Science · English
A selection of the best interviews conducted by physician leaders and recorded at cardiology conferences around the globe. 06f763f0-76e5-11f0-bb7c-8557ae1d8a8b
More from Talking Points All episodes →
-
6 May 2026 · 7 min
The VESALIUS-CV Trial
Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.
-
22 Apr 2026 · 5 min
The META-AF Trial
Amrish Deshmukh talks to C. Michael Gibson about the use of metformin as an adjunctive therapy to catheter ablation of AF.
-
1 Apr 2026 · 8 min
Evolution of Pharmacotherapy in STEMI
How has the pharmacotherapy for STEMI changed over the past 46 years? Ginger Jiang and C. Michael Gibson discuss treating patients with zalunfiban at first medical contact.
-
4 Mar 2026 · 6 min
The CorCMR Trial
Colin Berry and C. Michael Gibson discuss whether stress CMR imaging is helpful in patients with angina and no obstructive CAD.
-
4 Feb 2026 · 4 min
The TUXEDO-2 Trial
Sripal Bangalore and C. Michael Gibson discuss whether ticagrelor is noninferior to prasugrel in patients with diabetes and multivessel CAD undergoing PCI.
-
17 Dec 2025 · 16 min
The 2024 ESC CCS Guidelines
Mamas Mamas, Nieves Gonzalo, and Erick Schampaert take a look at the latest guidelines for chronic coronary syndromes and how they relate to complex PCI.
-
10 Dec 2025 · 6 min
The My Heart Your Heart Trial
Thomas Crawford meets with C. Michael Gibson to discuss the role of reconditioned pacemakers in low- and middle-income countries.
-
3 Dec 2025 · 14 min
The FAVOR III Europe Trial
Mamas Mamas, Birgitte Krogsgaard Andersen, and Niels Ramsing Holm discuss QFR versus FFR for guiding resvascularization in patients with coronary stenoses.
-
3 Dec 2025 · 6 min
The FLOW Trial
C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.
-
19 Nov 2025 · 14 min
STORM-PE TRIAL
James Benenati, Robert Lookstein, and Rachel Rosovsky discuss the STORM-PE trial, the first-of-its-kind RCT for acute intermediate-high risk pulmonary embolism (PE).
Take it with you
The Melo app keeps playing with the screen off, works in the car and on your watch, wakes you to your station, and browses the whole catalogue offline. Free, no ads, no account.
